

## Photodynamic Therapy with Bilirubin-Coated Nanoparticles

**Track Code:** 2019-WON-68496

**Categories:**

- Biomedical Engineering
- Pharmaceuticals

**Keywords:**

- Bilirubin
- Biomedical Engineering
- Cancer
- Nanoparticles
- Pharmaceuticals
- Photodynamic therapy
- Photosensitizer
- Radioluminescence
- Squamous Cell Carcinoma
- X-rays

Researchers at Purdue University have developed nanoparticles for use in photodynamic therapy that are activated by x-rays and can target tumors in deeper tissue. Photodynamic therapy currently uses photosensitizing agents to directly kill cancer cells and is used in combination with radiation therapy to enhance its anti-tumor effects. However, the therapy is limited to skin tumors because it requires photosensitizing agents that are activated by light in the UV-visible range, which can only pass through ~1/3 of an inch. Unlike other competing nanoparticle enhancers which require administration of systemic photosensitizing agents, these nanoparticles are coated with bilirubin which acts as the photosensitizer. The nanoparticles demonstrated a 1.4 fold improvement over x-rays alone in killing cancer cells in a cell survival assay. Applications for this technology are in the treatment of cancer.

**Advantages:**

- Localized delivery of therapy
- 1.4 fold improvement in killing cancer cells in vitro
- Low toxicity

**Potential Applications:**

- Photodynamic therapy
- Cancer treatment

Publication: Bilirubin-Coated Radio-Luminescent Particles for Radiation-Induced  
Photodynamic Therapy. ACS Applied Bio Materials 3(8),  
4858-4872, 2020 (DOI: 10.1021/acsabm.0c00354)

**People:**

- Won, You-Yeon (Project leader)
- Pizzuti, Vincenzo John

**Intellectual Property:**

**Application Date:** July 10, 2021

**Type:** NATL-Patent

**Country of Filing:** United States

**Patent Number:** (None)

**Issue Date:** (None)

**Application Date:** January 10, 2020

**Type:** PCT-Patent

**Country of Filing:** WO

**Patent Number:** (None)

**Issue Date:** (None)

**Application Date:** January 22, 2019

**Type:** Provisional-Patent

**Country of Filing:** United States

**Patent Number:** (None)

**Issue Date:** (None)

**Contact OTC:**

Purdue Office of Technology Commercialization  
The Convergence Center  
101 Foundry Drive, Suite 2500  
West Lafayette, IN 47906

Phone: (765) 588-3475

Fax: (765) 463-3486

Email: [otcip@prf.org](mailto:otcip@prf.org)